tiprankstipranks
Trending News
More News >
Bavarian Nordic A/S (BVNRY)
OTHER OTC:BVNRY
US Market

Bavarian Nordic (BVNRY) Earnings Dates, Call Summary & Reports

Compare
166 Followers

Earnings Data

Report Date
Aug 22, 2025
TBA Not Confirmed
Period Ending
2025 (Q2)
Consensus EPS Forecast
Last Year’s EPS
Same Quarter Last Year
Based on 0 Analysts Ratings

Earnings Call Summary

Earnings Call Date:May 09, 2025
|
% Change Since: 8.95%
|
Next Earnings Date:Aug 22, 2025
Earnings Call Sentiment|Positive
Bavarian Nordic's earnings call highlights strong revenue growth and a solid start to the year, driven by impressive performances in travel health and a new U.S. government contract. The successful launch of the Chikungunya vaccine further supports positive prospects. However, there are minor concerns regarding the public preparedness revenue shortfall and potential currency exchange risks. Overall, the positive aspects significantly outweigh the negatives.
Company Guidance
During the Bavarian Nordic Q1 2025 earnings call, the company reported a robust start to the fiscal year with almost DKK 1.4 billion in revenue, marking a 62% growth compared to the previous year. The EBITDA margin was strong at 31%. Key contributors to this performance included a solid manufacturing output that enabled the advancement of some public preparedness orders, and a new $144 million order from the U.S. government, boosting revenue for 2026. In the travel health sector, the company experienced significant growth in rabies and TBE vaccine sales, with market share gains in key areas like the U.S. and Germany. Additionally, the launch of the Chikungunya vaccine, VIMKUNYA, in the U.S., Europe, and U.K. contributed to the positive results. Bavarian Nordic maintains a full-year revenue guidance of DKK 5.7 to 6.7 billion and an EBITDA margin of 26% to 30%, despite currency fluctuations and other uncertainties.
Strong Revenue Growth
Bavarian Nordic recorded almost DKK1.4 billion in revenue, representing a 62% growth compared to the previous year.
EBITDA Margin Achievement
The company established an EBITDA margin of 31%, indicating a strong start to the year.
Travel Health Sales Surge
Travel health segment showed a 52% growth, driven by rabies and TBE vaccines, with rabies growing by 53% and TBE by 62%.
Chikungunya Vaccine Launch
Bavarian Nordic launched its Chikungunya vaccine, VIMKUNYA, which has been approved in the U.S., Europe, and the U.K., with initial sales recorded.
New Order from U.S. Government
A new order from the U.S. government (BARDA) for $144 million was secured, increasing existing contracts from DKK2.5 billion to DKK2.65 billion.
Gross Margin Improvement
Achieved a gross margin of 51%, two percentage points better than last year's full-year performance.
Future Growth in Travel Health
The travel health market is expected to grow at a 20% CAGR, with Bavarian Nordic well-positioned due to expanding endemic regions and new vaccine introductions.

Bavarian Nordic (BVNRY) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

BVNRY Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 22, 2025
2025 (Q2)
- / -
May 09, 2025
2025 (Q1)
- / 0.13
-0.071285.92% (+0.20)
Mar 05, 2025
2024 (Q4)
- / 0.47
0.565-17.17% (-0.10)
Nov 15, 2024
2024 (Q3)
- / 0.04
-0.213120.66% (+0.26)
Aug 22, 2024
2024 (Q2)
- / 0.16
0.336-52.08% (-0.18)
May 08, 2024
2024 (Q1)
- / -0.07
0.232-130.60% (-0.30)
Feb 21, 2024
2023 (Q4)
- / 0.56
0.097482.47% (+0.47)
Nov 16, 2023
2023 (Q3)
- / -0.21
0.008-2762.50% (-0.22)
Aug 23, 2023
2023 (Q2)
- / 0.34
-0.161308.70% (+0.50)
May 09, 2023
2023 (Q1)
- / 0.23
-0.194219.59% (+0.43)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

BVNRY Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
May 09, 2025
$7.82$8.29+6.01%
Mar 05, 2025
$7.69$8.08+5.07%
Nov 15, 2024
$9.68$7.96-17.77%
Aug 22, 2024
$12.28$13.52+10.10%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Bavarian Nordic A/S (BVNRY) report earnings?
Bavarian Nordic A/S (BVNRY) is schdueled to report earning on Aug 22, 2025, TBA Not Confirmed.
    What is Bavarian Nordic A/S (BVNRY) earnings time?
    Bavarian Nordic A/S (BVNRY) earnings time is at Aug 22, 2025, TBA Not Confirmed.
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is BVNRY EPS forecast?
          Currently, no data Available
          What am I Missing?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis